anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
Assistive devices are medical devices designed to support the individuals functions and increase their activities. Assistive devices are of critical importance for the independence and participation of disabled individuals in society and are of increasing interest today. The use of assistive devices is a process consisting of different steps to increase the individuals participation in daily life activities.

Although assistive devices cannot completely eliminate disability, they can increase independence by reducing negative effects. There are many problems encountered in the selection of assistive devices. The problems encountered include the cost of the assistive device, the necessary application training, service delivery, environmental factors, age, gender, level of disability, and the type of device used. The success of assistive device rehabilitation is affected by many factors such as the duration and correct use of the device by the individual, their attitude towards the assistive device, their participation in treatment, and their expectations.

In low-income countries, disabled individuals have the right to access affordable, available assistive devices such as prosthetics and orthotic services according to the Convention on the Rights of Persons with Disabilities. Prosthetic and orthotic services are limited in low-income countries. In order to improve mobility and ensure greater participation of people with physical disabilities and amputees in society, assistive devices should be increased and user satisfaction should be investigated. In todays prosthetic and orthotic field, low-cost devices need to be developed and the multi-faceted satisfaction of users needs to be evaluated in terms of improvements in rehabilitation programs. Test batteries are frequently preferred in the evaluation of user satisfaction in orthosis and prosthetic rehabilitation. Generally, surveys based on individuals; expectations, satisfaction, experiences during daily life and statements of the individual regarding their assistive device are preferred. When the literature is examined, it is seen that there are few studies evaluating the use of orthosis and prosthetic assistive devices in terms of patient satisfaction. The aim of this study is to investigate the multi-faceted satisfaction of individuals using assistive devices. Female/male individuals using upper extremity orthosis, lower extremity orthosis, trunk orthosis, lower or upper extremity prosthesis and/or assistive device will be included in the study on a voluntary basis. Quebec User Evaluation of Satisfaction with Assistive Technology (QUEST) survey is planned to be used for the evaluation of assistive technology user satisfaction, Orthotics and Prosthetics User\&#39;s Survey (OPUS) is planned to be used for the evaluation of orthosis prosthesis user satisfaction.
PURPOSE: To prepare a cosmetic composition for makeup having a high content of a silicone wax without requiring the addition of a surfactant by dispersing the silicone wax into an aqueous phase containing two types of water-soluble acrylic polymers. CONSTITUTION: This stable dispersion of a silicone wax containing &gt;=10 wt.% of a silicone wax is prepared in an aqueous phase by using two types of acrylic polymers. The first acrylic polymer comprises at least one copolymer of a 3-6C single double bond-containing acid or its acid anhydride and a long-chain acrylic ester and the other polymer comprises at least one homopolymer of acrylic acid or its salt or a copolymer thereof (except a copolymer of acrylic acid and a long-chain acrylic ester and its salt). The dispersion contains up to 60 wt.% of the silicone wax. The composition is used for a cosmetic composition and suitable for, e.g. a foundation, an eye shadow or a rouge.
NEW MATERIAL:A compound shown by the formulaI(R&lt;2&gt; is H or acetyl; AC is acetyl). EXAMPLE:3-0-[2-Acetamide-2-deoxy-3-0-( beta-D-galactopyranosyl )-beta-D-galactopyranosyl]-1,2-di-O-tetradecyl-sn-glycerol. USE:A biochemical reagent for elucidating immune function and an antimetabolite. PROCESS:A compound shown by the formula II is treated with phthalic anhydride, acetylated, and reacted with a compound shown by the formula III in the presence of a Lewis acid, to give a compound shown by the formula IV wherein the groups R&lt;1&gt; and R&lt;2&gt; are phthaloyl groups and the group R&lt;3&gt; is acetyl group. This compound is treated with an amine, acetic anhydride, subjected to N-acetylation, treated with benzaldehyde in the presence of a Lewis acid, and reacted with a compound shown by the formula V (X is halogen) in the presence of a mercury compound. The reaction product is oxidized and hydrolyzed, deacetylated in the presence of a base under reflux, to give a compound shown by the formulaIwherein the groups R&lt;1&gt; and R&lt;2&gt; are H.
1. Technical Result Simplification of delivery of medicaments for the treatment of Parkinson&#39;s disease. 2. Essence A pharmaceutical composition comprising pharmacologically effective amounts of entacapone, levodopa, and carbidopa, or pharmaceutically acceptable salts or hydrates thereof, and comprising at least one pharmaceutically acceptable excipient. To obtain said composition entacapone and levodopa are separately mixed and then carbidopa is added to the mixture. 3. Field of Application Medicine.
PROBLEM TO BE SOLVED: To easily obtain the subject compound as an intermediate for the synthesis of naphthyridone carboxylic acid including trovafloxacin, by reducing a specific compound in the presence of iron and an organic solvent under an acidic condition to form a specific compound and then acylating the compound with an acylating agent. SOLUTION: This compound of formula III is obtained by reducing a compound of formula I (R&lt;1&gt; is benzyl) in the presence of iron and an organic solvent under an acidic condition to form the corresponding compound of formula II, which, preferably without isolation, is then acylated with an acylating agent of the formula R&lt;2&gt; C(O)X [R&lt;2&gt; is a 1-6C alkyl, trifluoromethyl or a (substituted) phenyl; X is an eliminable group). The organic solvent is a 1-6C alcohol (e.g. ethanol) or an ether (e.g. tetrahydrofuran). The acidic condition is afforded by the use of a mineral acid (e.g. hydrochloric acid) or an organic acid (e.g. acetic acid).
The invention relates to liver protection, stomach invigorating anti-alcoholic Chinese medicine healthcare food and a preparation method thereof. Under the influence of high work stress in modern life, the number of people often drinking or often drinking heavily is increasing year by year, the number of patients suffering from headache, dizziness, gastritis, gastric cancer, alcoholic liver, fatty liver, cirrhosis, cholecystitis, pancreatitis and the like is on the sharp increase. The liver protection, stomach invigorating anti-alcoholic Chinese medicine healthcare food, Gan Cao Kang pill is prepared from pure natural plants which are published by the country to be not only food but also medicine. The Gan Cao Kang pill comprises liquorice, honeysuckle, smoked plum, hawthorn, fingered citron, chicken&#39;s gizzard-membrane, chrysanthemum, the fruit of Chinese wolfberry, semen Hoveniae, coix seed and fructus amomi. The liver protection, stomach invigorating anti-alcoholic Chinese medicine healthcare food has the advantages of tonifying liver and kidney, calming the heart and tranquilizing the mind, relieving alcoholism, helping digestion and invigorating stomach, improving symptoms of alcoholic liver and fatty liver of patients through dietary therapy, and improving sub-health status. Besides, the liver protection, stomach invigorating anti-alcoholic Chinese medicine healthcare food can relieve drunk dizziness and headache and stomach discomfort, and treat patients suffering from stomachache, gastritis, gastric ulcer, alcoholic liver, fatty liver, cholecystitis and the like due to long-term drinking.
A concentrate that is particularly useful as a pearling agent or for preparing emulsions is provided. The concentrate includes from 60 to 90% by weight of a mixture of at least one alkylglycoside of the formula RO(G) x  and of at least one alkylglycoside of the formula R&#39;O(G&#39;) x  &#39;. R represents a saturated or unsaturated linear or branched aliphatic radical containing from 8 to 15 carbon atoms. R&#39; represents a saturated or unsaturated linear or branched aliphatic radical containing from 16 to 22 carbon atoms. G and G&#39;, which are identical or different, represent a saccharide residue. The subscripts x and x&#39;, which are identical or different, represent a number between 1 and 10. The concentrate also includes from 10 to 40% by weight of at least one fatty alcohol of the formula R 1  OH, R 1  being a saturated or unsaturated linear or branched aliphatic radical containing from 8 to 22 carbon atoms.
A device, preferably in the form of a skin patch, is disclosed for usage in the delivery of a contactant to human skin for the purpose of treating medical conditions responsive to contact immunotherapy, without the presence of medication to alleviate contact dermatitis induced by the contactant. The skin patch specifically induces a cell-mediated contact dermatitis in the treatment of skin disorders. Its anticipated use pertains to treatment of, for example, human papilloma virus infections, or warts. In a first embodiment, a pressure activated single chambered skin patch is topically applied and used for controlled release of contactant to human skin. In a second embodiment, a pressure activated two-chambered skin patch is topically applied and used for controlled release of a contactant to human skin. Alternatively, a single chambered skin patch is topically applied and hydrated by the contacted skin for release of contactant. In an additional embodiment, the contactant may be applied separately of the skin patch portion, in a manner that maintains the contactant in contact with the patient&#39;s skin for the predetermined period of time necessary to cause sufficient contact dermatitis to effect resolution of the medical condition.
A non-invasive remote diagnostic system includes a central processing unit (CPU) 10 adapted to feed an image of a patient such as a digital photograph to be displayed to an operator by a first computer monitor 21. A second computer monitor 22 is displaying a realistic outline of a target area of diagnostic interest such as an outline of a human organ or a particular portion thereof. These two monitors together with a CPU are adapted to induce a state of heightened consciousness and intuition of a system operator. A detecting/evaluating unit 30 is sensing non-invasively the operator&#39;s biofeedback response while the operator is exposed to the images. The biofeedback response is converted to an electrical signal and is fed back into the CPU 10 to compare against a predetermined database of similar signals obtained from volunteers with known diseases. The biofeedback signal allows a non-invasive remote diagnosis of a patient&#39;s state of health.
A wireless device, an app on a wireless device, and a method for automated diagnosis of radiographs is described. The app prompts a user to capture a photograph of a radiograph external to the mobile device with the mobile device&#39;s camera. The quality of the photograph is assessed and an error condition is reported if the quality is insufficient. A module displays on the mobile device display (1) a diagnosis that is assigned to the radiographs and (2) at least one similar radiograph. The diagnosis is assigned by subjecting the photograph to a deep learning model trained on a large corpus of labelled radiographs. The deep learning model can be resident on the mobile device or in a back end server. The app includes tools for enabling the user to select and navigate the input photograph and the similar radiograph by means of hand gestures on the display, and a tool for displaying medical knowledge associated with the diagnosis.
Cancerous cells and HIV-infected cells secrete  alpha -N-acetylgalactosaminidase into the blood stream, resulting in deglycosylation of serum Gc protein. This inactivates the MAF precursor activity of Gc protein, leading to immunosuppression. Thus, both  alpha -N-acetylgalactosaminidase activity and MAF precursor activity of Gc protein in patient blood stream can serve as diagnostic and prognostic indices. In one embodiment is disclosed a process for determining macrophage activating factor precursor activity in plasma or serum of a person suspected of having cancer or HIV, comprising the step of quantifying in the plasma or serum an amount of vitamin D3-binding protein. The determination of the macrophage activating factor precursor activity provides an indication of the patient&#39;s capability to activate its own monocytes/macrophages. In another embodiment is disclosed a process for determining macrophage activating factor precursor activity in plasma or serum of a person suspected of having cancer or HIV comprising the step of quantifying in the plasma or serum an amount of  alpha -N-acetylgalactosaminidase activity. Determining the  alpha -N-acetylgalactosaminidase activity in the plasma or serum provides an indication of a quantity of malignant cells (or HIV) in the plasma or serum.
The method of the present invention quantifies the severity of a subject&#39;s neurodegenerative disorder. The subject answers a questionnaire which results in a patient-reported outcome dataset. Benchmark tests are carried out by the subject performing one or more tasks resulting in a task result dataset. Continuous sensors collect data resulting in a sensor dataset. Short assessment tests of the subject are conducted resulting in a short assessment dataset. The patient-reported outcome dataset, task result dataset, sensor dataset, and short assessment dataset are aggregated into an output dataset that includes non-motor outcome measures and motor outcome measures. A single score is generated that quantifies the severity of a neurodegenerative disorder of the subject based on the output dataset.
Application of luteolin as a food nutrient for inhibiting ochratoxin A nephrotoxicity is provided. LUT exerts its preventive effect by restoring cell viability and preventing LDH release. It reduces OTA-induced oxidative stress and lipid peroxidation by reducing ROS accumulation, improving mitochondrial membrane potential reduction, and restoring antioxidant enzyme activity to a control level. The regulation and control functions of Nrf2 and HIF-1 alpha in the process are analyzed and evaluated through a cellular immunofluorescence experiment, a reporter gene plasmid transfection experiment and a fluorescent quantitative PCR reaction. The results indicate that LUT activates Nrf2 pathway, improving the cells&#39; ability to defend against oxidative damage caused by OTA. In addition, LUTs promote post-injury repair of cells by regulating the HIF-1 α pathway, initiating angiogenic and epithelial repair processes. The invention discloses that the LUT as a flavonoid dietary supplement has good application potential in the aspect of inhibiting OTA and other mycotoxins, and can be developed into food nutrients for inhibiting OTA nephrotoxicity, thereby expanding the application of the LUT.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a supplement set for reducing at least one of symptoms out of dysmenorrhea and premenstrual syndrome.  &lt;P&gt;SOLUTION: The supplement set is used for reducing at least one of symptoms out of dysmenorrhea and premenstrual and contains at least a supplement for an ovarian follicle term ingested in the ovarian follicle term. Preferably, the supplement set further contains a supplement for a menstrual term ingested in the menstrual term and a supplement for a luteal phase ingested in the luteal phase. Especially, the supplement for the ovarian follicle term contains vitamin A, β-carotene, cystine, vitamin B6, vitamin B12, vitamin C, vitamin E, folic acid and the like. The supplement for the menstrual term further contains hesperidin, raspberry fruit juice, a hawthorn (crataegus oxyacantha) extract, a grape seed extract, CA, Mg and Fe. The supplement for the luteal phase further contains theanine, soybean isoflavone and the like.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, and can be used if extremity vein catheterisation is required for multiple intravenous introduction of drug solutions. That is ensured by vein catheterisation followed by change of an extremity position with respect to a patient&#39;s trunk so that an open pavilion of the catheter is arranged below a level of a patient&#39;s right atrium. An infrared imager is used to monitor an extremity surface condition within a projection of the catheter. If observing a region of local hyperthermia along the vein, its content is examined by ultrasound. A thrombus if any is sized up; tourniquets are applied below and above the region of local hyperthermia to complete sanguimotion cessation in the vein. Then, blood is taken from the vein to its devastation, and the volume of taken blood portion is measured that is followed by introduction of 2% lidocaine hydrochloride 0.5 ml and a thrombolytic solution at temperature +42C in the volume necessary for complete vein filling. 3 minutes later, the whole liquid vein content is removed through the catheter, and the tourniquets are released, the vein content is examined by ultrasound. The presence of a thrombus requires another 3-minute tourniquet application with venous blood replacement by a local anaesthetic solution with a thrombolytic agent to stabilise thrombus size, then the catheter is removed, and the drugs are introduced by means of another catheter which is inserted in another extremity vein. ^ EFFECT: method allows higher safety and effectiveness of vein catheterisation due to early phlebitis detection and exact delivery of fibrinolytic agents to the thrombus to dissolve a &#34;fresh&#34; portion of the thrombus that allows reducing a risk of thromboembolism. ^ 1 ex
396,055. Dentifrices. GULBRANSEN, S. G., Larvik, Norway. Jan. 22, 1932, No. 2007. Convention date, Jan. 23, 1931. [Class 131.] A tooth paste is prepared by evaporating the juice of fruit or berries to a syrup, filling such syrup into&#39; tubes, and then cooling, the syrup being initially of such consistency that when cooled it thickens into a paste which is selfpreserving. The juice is normally evaporated to one-third to one-fifth of its volume, but in the case of juice having a low solid content or a low percentage of constituents having a preserving character, further evaporation may be necessary. Glycerine up to 5 per cent, or a thickening agent up to 20 per cent of the final product, may be added to the juice before evaporation. Suitable thickening agents are soapstone powder, asbestos powder, prepared chalk, or clay. In examples the paste is prepared from tomato juice containing 1 per cent of glycerine, and from the juice of red whortleberries mixed with 10 per cent of prepared chalk and 1 per cent of glycerine.
PROBLEM TO BE SOLVED: To obtain a multidrug resistance-overcoming agent and anticancer function promotor, free from calcium antagonistic activity, having a low cytotoxicity and capable of overcoming multidrug resistance of a cancer by compounding a specific solanesylethylenediamine derivative as an active component. SOLUTION: This agent contains a compound of formula I [(n) is 5-12; R1 and R2 are each a benzyl group (the phenyl ring of the benzyl group can be substituted with OH, an alkyl, an alkoxy, a halogen or methylenedioxy), but the case where R1 and R2 are each formula II at the same time is excluded] or a pharmaceutically permissible salt of the compound. As an example of a compound of formula I, N,N&#39;-bis(3,4diethoxybenzyl)-N solanesylethylenediamine of formula III is cited. A compound of formula 1 is obtained e.g. by reacting a compound of formula IV with a compound of formula V (X is a leaving group such as a halogen). This drug composition is useful as an anticancer function promoter on an anticancer agent for brain tumor, kidney cancer, adrenal cancer, large intestinal cancer, small intestinal cancer, colon cancer, lung cancer, liver cancer, etc.  As an anticancer agent, taxol or its derivative is suitable.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method and an apparatus for manufacturing a uniform-sized particle containing a lipophilic compound by covering the surface of a droplet of the lipophilic compound which is unstable against water, light, oxygen, or the like with a covering agent.  &lt;P&gt;SOLUTION: An emulsion dispersion 2 containing fat-soluble vitamins is contained inside a dispenser 1 and dropped from a hollow-bore needle 3 at the tip of the dispenser 1 onto the covering agent 8 fed from a feeder 7. This enables the surface of the droplet of the emulsion dispersion 2 to be covered with the covering agent 8. The obtained covered particle 4 is passed through a sieve 10 to be separated from the excessive covering agent 8, and the separated covered particle 4 is heated to dry the moisture therein. The obtained covered particle 4 has a size substantially equal to the diameter of the hollow-bore needle 3 at the tip of the dispenser 1, and the unstable, fat-soluble vitamins can be provided as the uniform-sized particle.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
In one embodiment, a medical device information technology (&#34;IT&#34;) data transmission system includes a cluster domain, an external domain, and an interface domain. Devices belonging to the cluster domain may communicate in real-time such that availability, security, reliable integrity and performance are guaranteed. The external domain includes devices that are not enabled by direct inclusion in the clustered domain, and may include devices for external information systems, presentation devices, personal computer devices, shared medical devices, and bedside medical devices. The interface domain enables the out-of-domain devices to communicate with the cluster devices in a bi-directional manner. Communication may be through some access nodes in the cluster. The access node enables exchange of information between the open outside domain and the closed and private cluster domains.
&lt;P&gt;PROBLEM TO BE SOLVED: To easily and efficiently process a job for preparing a medicine as prescribed in a dispensary.  &lt;P&gt;SOLUTION: A dispensary support system is provided with a POS system 11, a reception controller 12 and an IC card issuing machine 13, and an article is stuck with a barcode 40 presenting article information. When a prescription 30 is received from a patient 10, the medicine is prepared according to the prescription, the barcode 40 is read by a scanner 15a of a mobile input apparatus 15, and a quantity is inputted from a ten key 15b. In a POS register 14, an IC card 20 carried with the patient 10 is read, prescribed medicine information is read from the mobile input apparatus 15, and they are transferred to the receipt computer 12. In the receipt computer 12, based upon such information, the demand amount of the medicine is calculated and transferred to the POS register 14. In the POS register 14, the demand amount is displayed, settlement is performed, and the medicine is delivered to the patient 10 together with a receipt. Based upon barcode information and IC card information, a medicine history management/insurance demand processing job is performed wile being linked with money dispensing processing or the like.  &lt;P&gt;COPYRIGHT: (C)2004,JPO